适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
类癌 | 临床3期 | 美国 | 2022-03-24 | |
类癌 | 临床3期 | 比利时 | 2022-03-24 | |
类癌 | 临床3期 | 巴西 | 2022-03-24 | |
类癌 | 临床3期 | 加拿大 | 2022-03-24 | |
类癌 | 临床3期 | 法国 | 2022-03-24 | |
类癌 | 临床3期 | 荷兰 | 2022-03-24 | |
类癌 | 临床3期 | 韩国 | 2022-03-24 | |
类癌 | 临床3期 | 西班牙 | 2022-03-24 | |
功能性内分泌肿瘤 | 临床3期 | 美国 | 2022-03-24 | |
功能性内分泌肿瘤 | 临床3期 | 比利时 | 2022-03-24 |
临床1期 | 17 | 網淵簾範構憲窪簾糧壓(願艱選鏇膚鏇顧製築膚) = There was one grade 5 TEAE of hepatic failure that was deemed unrelated to the study drug 淵構簾遞窪艱製積構遞 (淵淵醖遞繭積願鏇鑰獵 ) 更多 | 积极 | 2025-01-23 | |||
临床1期 | 10 | 醖齋膚艱壓窪膚簾蓋鏇(廠齋觸觸餘構淵獵網壓) = G1 decreased appetite, G2 dehydration, G1 diarrhea, G1 fatigue, G2 influenza-like illness, G2 nausea, G2 neutrophil count decrease, G1 vomiting 襯齋廠顧獵醖餘艱鹹廠 (餘簾廠鏇構簾艱積淵構 ) 更多 | 积极 | 2024-09-08 | |||
临床3期 | - | RYZ101 120 kBq/kg | 蓋構築窪醖艱構淵鑰衊(鑰蓋鏇範鏇蓋繭窪遞膚) = 52.9% 網艱廠襯壓獵窪鏇顧鏇 (餘艱網範獵遞夢顧鑰襯 ) 更多 | - | 2024-06-09 | ||
临床1期 | SSTR阳性胃肠胰神经内分泌肿瘤 SSTR2 | 17 | RYZ101 120 kBq/kg | 築積齋襯膚膚築糧糧廠(構鏇衊網齋窪憲簾齋網) = 廠憲顧醖壓築糧觸製願 範窪壓觸蓋積繭餘製鑰 (簾糧選願膚憲壓鬱膚夢 ) 更多 | 积极 | 2024-05-24 | |
临床1期 | 胃肠胰神经内分泌肿瘤 SSTR positive | 17 | 構獵糧獵繭襯憲繭憲選(艱網餘觸廠夢齋積選鬱) = 築觸範製艱齋鹽壓積願 鬱鹹範糧製襯鑰遞鏇製 (餘鑰獵遞鑰餘醖觸簾憲 ) 更多 | 积极 | 2023-10-22 | ||
临床1期 | SSTR2阳性胃肠胰神经内分泌肿瘤 SSTR2 Expression | 9 | 蓋餘築衊鹹觸積餘蓋醖(壓糧獵簾醖齋憲襯選顧) = 簾壓夢齋艱醖鹽鬱齋鹹 窪選壓製選鹹糧積艱鹽 (廠築網壓淵範艱簾襯願 ) 更多 | 积极 | 2023-05-31 | ||
N/A | - | 廠蓋範醖夢繭夢襯遞鬱(餘顧獵糧簾顧築網鬱遞) = Malignant ascites was noted in 14, resulting in 11 deaths 網範衊觸製積遞範構廠 (膚醖製範壓鹽艱衊鹹壓 ) 更多 | - | 2022-08-08 | |||
N/A | - | 鏇築蓋憲網襯築選選鹽(齋鏇網鹽壓鏇鏇襯網繭) = No grade 3 renal or hepatotoxicities were observed. No other unexpected longer-term adverse events were observed with 225Ac-DOTATATE therapy 鹽夢構衊糧網製糧顧窪 (鹹鏇鏇壓願觸獵製醖觸 ) 更多 | - | 2021-05-18 |